Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China
Clinical trial evaluated the safety and tolerability of 30 mg dose for the treatment of vasomotor symptoms (VMS) associated with menopause TOKYO, Sept. 4, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., …